SIGNIFICANT ACCOUNTING POLICIES (Details) $ / shares in Units, $ in Thousands					1 Months Ended	3 Months Ended
	Aug. 29, 2022	May 13, 2021 USD ($)	Jul. 23, 2018 USD ($)	Oct. 19, 2017 USD ($)	Oct. 31, 2015	Mar. 31, 2024 USD ($) agreement $ / shares shares	Mar. 31, 2023 USD ($) shares	Dec. 31, 2023 USD ($) $ / shares	Feb. 27, 2023 USD ($)	Jul. 02, 2021 USD ($) $ / shares
Significant Accounting Policies [Line Items]
Number of global licensing and supply agreements | agreement						2
Common Stock, Par or Stated Value Per Share | $ / shares						$ 0.001		$ 0.001
Stock issuance proceeds							$ 14,233
Aggregate principal amount						$ 20,420		$ 20,251
Antidilutive securities excluded from computation of earnings per share, amount | shares						31,839,345	36,292,208
Accumulated deficit								$ 381,549
ATM Shares
Significant Accounting Policies [Line Items]
Number of shares issued (in shares) | shares							13,980,060
Common Stock, Par or Stated Value Per Share | $ / shares										$ 0.001
Sale of stock, maximum offering price						$ 6,400			$ 20,000	$ 20,000
Stock issuance proceeds							$ 20,000
2024 Notes
Significant Accounting Policies [Line Items]
Interest rate (as a percent)						7.50%
Minimum cash balance required						$ 7,500
Amended Pfizer Agreement | Protalix Bio Therapeutics Incorporation | Brazil
Significant Accounting Policies [Line Items]
Collaborative arrangement revenues and expenses sharing percentage					100.00%
Chiesi Agreements
Significant Accounting Policies [Line Items]
Amount of milestone payment received						$ 20,000
Chiesi US Agreement
Significant Accounting Policies [Line Items]
Additional amounts payable to cover development costs			$ 20,000
Additional amount payable for achievement of regulatory and commercial milestones			$ 760,000
Chiesi US Agreement | Minimum
Significant Accounting Policies [Line Items]
Payment on net sales percentage			15.00%
Chiesi US Agreement | Maximum
Significant Accounting Policies [Line Items]
Payment on net sales percentage			40.00%
Chiesi Ex-US Agreement
Significant Accounting Policies [Line Items]
Additional amounts payable to cover development costs				$ 25,000
Agreement amendment payment receivable		$ 10,000
Change in amount receivable for achievement of regulatory and commercial milestones		$ 25,000
Additional amount payable for achievement of regulatory and commercial milestones				$ 320,000
Chiesi Ex-US Agreement | Minimum
Significant Accounting Policies [Line Items]
Payment on net sales percentage				15.00%
Chiesi Ex-US Agreement | Maximum
Significant Accounting Policies [Line Items]
Payment on net sales percentage				35.00%
Chiesi US Agreement and Chiesi Ex-US Agreement
Significant Accounting Policies [Line Items]
Non-refundable payment receivable			$ 25,000	$ 25,000
Fill/Finish Agreement
Significant Accounting Policies [Line Items]
Extended term of agreement	7 years